CHF58.10
0.52% day before yesterday
SIX Swiss Exchange, Dec 27, 05:30 pm CET
ISIN
CH0012530207
Symbol
BANB
Sector
Industry

Bachem Holding Stock price

CHF58.10
-9.40 13.93% 1M
-24.85 29.96% 6M
-6.90 10.62% YTD
-7.45 11.37% 1Y
-77.70 57.22% 3Y
+26.78 85.50% 5Y
+48.38 497.74% 10Y
SIX Swiss Exchange, Closing price Fri, Dec 27 2024
+0.30 0.52%
ISIN
CH0012530207
Symbol
BANB
Sector
Industry

Key metrics

Market capitalization CHF4.36b
Enterprise Value CHF4.18b
P/E (TTM) P/E ratio 38.35
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.24
P/S ratio (TTM) P/S ratio 7.54
P/B ratio (TTM) P/B ratio 3.33
Dividend yield 1.38%
Last dividend (FY23) CHF0.80
Revenue growth (TTM) Revenue growth 7.65%
Revenue (TTM) Revenue CHF577.77m
EBIT (operating result TTM) EBIT CHF129.00m
Free Cash Flow (TTM) Free Cash Flow CHF-48.15m
EPS (TTM) EPS CHF1.51
P/E forward 36.42
P/S forward 7.14
EV/Sales forward 6.85
Show more

Is Bachem Holding a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Bachem Holding Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Bachem Holding forecast:

3x Buy
38%
4x Hold
50%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Bachem Holding forecast:

Buy
38%
Hold
50%
Sell
13%

Financial data from Bachem Holding

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
578 578
8% 8%
100%
- Direct Costs 398 398
5% 5%
69%
179 179
13% 13%
31%
- Selling and Administrative Expenses - -
- Research and Development Expense 13 13
19% 19%
2%
169 169
16% 16%
29%
- Depreciation and Amortization 40 40
13% 13%
7%
EBIT (Operating Income) EBIT 129 129
18% 18%
22%
Net Profit 114 114
15% 15%
20%

In millions CHF.

Don't miss a Thing! We will send you all news about Bachem Holding directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bachem Holding AG engages in the provision of peptides and oligonucleotides. It operates through the Europe/Asia and North America geographical segments. It offers project management, research grade production, catalog peptides, peptide NCES, and commercial NCES. The company was founded in 2003 and is headquartered in Bubendorf, Switzerland.

Head office Switzerland
CEO Thomas Meier
Employees 2,006
Founded 2003
Website www.bachem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today